Francesco Bertoni
frbertoni.bsky.social
Francesco Bertoni
@frbertoni.bsky.social
Institute of Oncology Research. President, ICML Local Organizing Committee. USI. Personal opinions only. #lymsm #lymphoma
Reposted by Francesco Bertoni
#IORnews
🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer.

Learn more: ior.usi.ch/events-news/...
November 6, 2025 at 8:30 AM
Reposted by Francesco Bertoni
Yesterday we had our first 19-ICML Local Organising Committee meeting — the behind-the-scenes work for the next edition has officially begun! 💥

@frbertoni.bsky.social

#19ICML #ICML #lymphoma #CLL #myeloma #lymssm
October 30, 2025 at 9:19 AM
Here are the 4 abstracts exploring novel therapeutics for patients with marginal zone lymphomas we're presenting at the #Targets25:
-Epigenetic vulnerabilities in marginal zone lymphoma
doi.org/10.1158/1535...
@iorbellinzona.bsky.social @usi.ch
Abstract C027: Epigenetic vulnerabilities in marginal zone lymphoma
AbstractBackground.. Alterations in chromatin-associated proteins contribute to the rewiring of transcriptional networks, promoting lymphomagenesis, disease progression, and resistance to therapies. T...
doi.org
October 25, 2025 at 10:58 AM
Reposted by Francesco Bertoni
#IORnews
An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma.

Learn more: ior.usi.ch/events-news/...
October 16, 2025 at 11:44 AM
Our letter by Nicolas Munz on in vitro lymphoma models for polatuzumab vedotin is now online in the British Journal of Haematology. Thanks to everybody at @iorbellinzona.bsky.social @usi.ch @snsf.ch

onlinelibrary.wiley.com/doi/10.1111/...
Polatuzumab vedotin and CD79B: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma
Click on the article title to read more.
onlinelibrary.wiley.com
October 8, 2025 at 4:40 AM
The review article, written in collaboration with Camille Laurent, on the biology of marginal zone lymphomas is now published in Blood. @iorbellinzona.bsky.social @usi.ch Università della Svizzera italiana @snsf.ch

doi.org/10.1182/bloo...
The Biology of MZL subtypes: Challenge and Relevance of Classification
Marginal zone lymphomas (MZLs) are a heterogeneous group of low-grade B-cell neoplasms classified into different entities by the current lymphoma classific
doi.org
October 2, 2025 at 2:45 PM
“Recent Advances in Treating Diffuse Large B-Cell Lymphoma “ by Jim Armitage
ascopost.com/issues/june-...
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...
ascopost.com
September 23, 2025 at 3:44 AM
A work, by Filippo Spriano in our lab, exploring the mechanisms of resistance to TK216, a molecule that targets ETS factors, is now available in bioRxiv

www.biorxiv.org/content/10.1...
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implica...
www.biorxiv.org
September 21, 2025 at 4:37 AM
Our collaborative work with Sebastian Patzke and Jostein Dahle on the CD37 targetting radioimmunoconjugated antibody 177Lu-lilotomab satetraxetan (Betalutin) is out in the British Journal of Haematology.
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
September 19, 2025 at 3:43 AM
Thanks to a collaboration with Francesco Buonocore and Maria Luisa Mangoni, we explored antimicrobial peptides (AMPs) in marginal zone lymphomas. The initial work by Filippo Spriano and others at the @iorbellinzona.bsky.social, is now available. @usi.ch
www.biorxiv.org/content/10.1...
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies
Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptid...
www.biorxiv.org
September 18, 2025 at 3:51 AM
A screening of the Irish marine biorepository identified a new bryostatin analog active in lymphomas. Nice collaboration with Olivier Thomas, his team, Filippo Spriano and other members of our @iorbellinzona.bsky.social lab. @usi.ch @sib.swiss
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B‐Cells Diffuse Large B‐Cell Lymphoma
Bryostatin analogs are found to be accumulated in the nudibranch Antiopella cristata collected in Irish waters. These are found to be potent inhibitors of activated B-cells diffuse large B-cell lymph....
chemistry-europe.onlinelibrary.wiley.com
September 13, 2025 at 5:57 AM
Registrations are open for the next LyFE - Lymphoma Forum of Excellence
«What's new in lymphoid neoplasias?», Bellinzona, Switzerland, February 2026
www.lymphomaforum.ch
Home
www.lymphomaforum.ch
September 12, 2025 at 8:21 AM
Reposted by Francesco Bertoni
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.

Learn more: tinyurl.com/ytybcbr8
September 9, 2025 at 8:26 AM
Project Hail Mary by Andy Weir: a very nice reading!
en.wikipedia.org/wiki/Project...
Project Hail Mary - Wikipedia
en.wikipedia.org
August 29, 2025 at 5:33 AM
Reposted by Francesco Bertoni
📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines

🔗 buff.ly/2ZYJc2c
August 5, 2025 at 9:12 AM
new ESMO Lymphoma Clinical Practice Guideline for diagnosis, treatment and follow-up
www.esmo.org/guidelines/e...
www.esmo.org
August 5, 2025 at 5:34 PM
Reposted by Francesco Bertoni
A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.

If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.

pls share 🙏
August 4, 2025 at 2:39 PM
Reposted by Francesco Bertoni
Here is a curated list of #patienteducation resources in Simplified or Traditional #Chinese on #health- or #cancer- related topics available from US, UK, EU, Australia, Singapore, Hong Kong, Taiwan, and India. We are curating support groups in US - input needed

blogs.hear2care.org/patientresou...
中文漢語醫患資訊 – blogs.hear2care.org
blogs.hear2care.org
August 3, 2025 at 9:46 PM
“The Best Song From Every David #Bowie Album” by Ultimate Classic Rock: I largely agree but I would have chosen differently from some album. Difficult sometime to select only one song. Bowie is still the best one.

ultimateclassicrock.com/david-bowie-...
David Bowie's Best Song From Each of His Albums
David Bowie's career reflects a rich evolution in music and persona, showcasing his vast influence across genres from rock to jazz.
ultimateclassicrock.com
August 2, 2025 at 5:53 AM
Sonic Youth’s Daydream Nation amazed when they came out and I still listen to it. Wonderful album and band.

www.udiscovermusic.com/stories/soni...
The Best Sonic Youth Songs: Alternative Classics
Such is the consistency and variety of their extensive catalogue, it's almost impossible to make a definitive best Sonic Youth songs list.
www.udiscovermusic.com
July 27, 2025 at 6:21 AM
Circulating miRNA in lymphomas. The work by Giulia Regazzo from Maria Giulio Rizzo’s group in Rome is out in the BJH. Glad to have contributed. @iorbellinzona.bsky.social @usi.ch

onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
July 21, 2025 at 7:22 AM
Our very interesting work on CXCR4 inhibition to increase the activity of therapies in B-cell lymphomas is now available in bioRxiv. Thanks to Laura Barnabei, Alberto Arribas, and all the contributors. @iorbellinzona.bsky.social @sib.swiss @usi.ch

www.biorxiv.org/content/10.1...
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various ...
www.biorxiv.org
July 15, 2025 at 1:44 PM